Episode 9

full
Published on:

15th Nov 2021

Dr Dana Flavin share her Low Dose Naltrexone (LDN) and Cancer Experience

Prof. Dr Dana Flavin Talks about LDN and Cancer treatments and shares over 30 years of experience.

Prof. Dr. Dana Flavin's training and background are extensive! She is a scientist, a doctor, and very knowledgeable about nutrition. She dedicates most of her time to her Cancer patients with great success. With over 30 years of experience and 10 years of utilizing LDN along with other conventional medications and therapies, she has great success.

She continues to research every avenue of treatment and is open-minded and curious. You will learn about and understand Cancer and how LDN has amazed her in hundreds of cases. She hopes studies will prove how effective LDN is for Cancer and other autoimmune conditions. This interview is one of my favorites!

Review by Ken Bruce

Listen for free

Show artwork for The LDN Radio Show About Low Dose Naltrexone

About the Podcast

The LDN Radio Show About Low Dose Naltrexone
Listen to LDN Prescribers, Researchers, Pharmacists from around the world! This is your chance to ask your questions to the experts, please email linda.ldnrt@gmail.com if you have any questions.
Listen to LDN Prescribers, Researchers, Pharmacists from around the world discuss Low Dose Naltrexone.

This is your chance to ask your questions to the experts, please email linda@ldnrt.org with your questions.

The LDN Radio Show is FREE if you would like to make a donation please visit www.ldnresearchtrust.org/donate

About your host

Profile picture for Linda Elsegood

Linda Elsegood

Linda is the founder of the LDN Research Trust established in 2004. She runs the trust raising awareness of LDN, answering with the help of the medical adviser’s, questions from users and the medical profession, helping people around the world find an LDN prescribing doctor. Linda has interviewed so far over 320 LDN Prescribing Doctors, Scientists and Users. Linda has MS and has been taking LDN with great success for MS over the last 10 years.